Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Atrium Therapeutics, Inc.RNA · Entity 6185 | Director | February 27, 2026 | March 02, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director · President and CEO | August 24, 2026 | August 24, 2026 |
| PUMA BIOTECHNOLOGY, INC.PBYI · Entity 5478 | Director | September 14, 2026 | September 17, 2026 |
| Zosano Pharma CorpZSAN · Entity 12518 | Director | January 02, 2019 | July 18, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Atrium Therapeutics, Inc.
Report date February 27, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.75 · Expires 2036-02-27 | Direct | 20,000 |
Reported balance
After 2026-02-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-27 · Grant · Acquired 20,000 · Balance 20,000 F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on February 27, 2026 and the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
Kura Oncology, Inc.
Report date August 24, 2026 · Filed August 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby One Fish Two Fish Revocable Trust | 479,194 |
Reported balance
After 2026-08-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-24 · Purchase · Acquired 100,000 · Balance 479,194 F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | Indirectby Lorax Charitable Remainder Unitrust | 300,000 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 300,000 |
| Common StockSEC Table I · non-derivative | Direct | 435,456 |
Reported balance
Holding disclosure · report date 2026-08-24 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 435,456 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $11.47 to $12.85. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
PUMA BIOTECHNOLOGY, INC.
Report date September 14, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,750 |
Reported balance
After 2026-09-14 transaction · row 1
1 source rowRow 1 · 2026-09-14 · Sale · Disposed 5,000 · Balance 54,750 F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #1 | 400 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 400 |
| Common StockSEC Table I · non-derivative | IndirectBy Child #2 | 150 |
Reported balance
Holding disclosure · report date 2026-09-14 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 150 |
Filing footnotes · ownership attribution and instrument terms
F1: Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
Zosano Pharma Corp
Report date January 02, 2019 · Filed July 18, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.34 · Expires 2029-01-02 | Direct | 1,500 |
Reported balance
After 2019-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-01-02 · Grant · Acquired 1,500 · Balance 1,500 F1: The shares underlying the option shall vest on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest on the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 65,091 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 13,711 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.09 · Expires 2031-06-15 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2020 Filed Sep 10, 2020 22:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 37,030 | $28.00 | $1,036,840.00 |
DisclosureSEC source: 0001209191-20-050028 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| September 10, 2020 Filed Sep 10, 2020 22:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 37,030 | $6.15 | $227,734.50 |
DisclosureSEC source: 0001209191-20-050028 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,126 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| September 10, 2020 Filed Sep 10, 2020 22:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 1,025 | $28.00 | $28,700.00 |
DisclosureSEC source: 0001209191-20-050028 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 305,711 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| September 08, 2020 Filed Sep 10, 2020 22:05 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 50,000 | $26.00 | $1,300,000.00 |
DisclosureSEC source: 0001209191-20-050028 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 306,736 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 215 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · derivative · entry 10 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,945 Underlying: Common Stock · 215 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments commencing on January 29, 2016. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 22,838 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · derivative · entry 9 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,977 Underlying: Common Stock · 22,838 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F5 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on January 23, 2017. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 23,053 | $22.37 | $515,787.82 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 215 | $4.80 | $1,032.00 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,149 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 25, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 22,838 | $6.15 | $140,453.70 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 6,568 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · derivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,160 Underlying: Common Stock · 6,568 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F4 · derivative.exercise_date: This option vested in 48 equal monthly installments commencing on January 29, 2016. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 6,568 | $22.04 | $144,769.89 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.13. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 24, 2020 Filed Aug 26, 2020 22:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 6,568 | $4.80 | $31,526.40 |
DisclosureSEC source: 0001209191-20-048438 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 19, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 11,913 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · derivative · entry 12 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,728 Underlying: Common Stock · 11,913 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F6 · derivative.exercise_date: This option vested in 48 equal monthly installments commencing on January 29, 2016. Read SEC document |
| August 19, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 11,913 | $22.09 | $263,196.29 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 9 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F5 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 11,913 | $4.80 | $57,182.40 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 521 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · derivative · entry 11 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,641 Underlying: Common Stock · 521 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F6 · derivative.exercise_date: This option vested in 48 equal monthly installments commencing on January 29, 2016. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 521 | $22.00 | $11,462.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 521 | $4.80 | $2,500.80 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,617 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 12,901 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · derivative · entry 10 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,162 Underlying: Common Stock · 12,901 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F6 · derivative.exercise_date: This option vested in 48 equal monthly installments commencing on January 29, 2016. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 12,901 | $22.00 | $283,868.44 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. F4 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $22.05. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 12,901 | $4.80 | $61,924.80 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2019 and amended on December 23, 2019 and June 8, 2020. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | SaleCommon Stock | 50,000 | $22.00 | $1,100,000.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 3 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Araxes Pharma LLC Disclosed balance after: 356,736 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2019 and amended on June 8, 2020. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 26,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,795,017 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:38 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 26,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-047616 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,096 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the sale of securities. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionSeries C Preferred Stock · Derivative | 108,504 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036981 · doc4.xml · derivative · entry 9 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 51,436 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionSeries B Preferred Stock · Derivative | 35,374 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036981 · doc4.xml · derivative · entry 8 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 16,769 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionSeries A Preferred Stock · Derivative | 254,907 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036981 · doc4.xml · derivative · entry 7 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 0 Underlying: Common Stock · 120,837 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.exercise_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. F1 · derivative.expiration_date: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 16, 2020 Filed Jun 16, 2020 20:29 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | ConversionCommon Stock | 189,042 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-036981 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By family trust Disclosed balance after: 805,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at a ratio of one-for-2.1095 shares, immediately prior to the consummation of the Issuer's initial public offering. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 20:36 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | SaleCOMMON STOCK | 25,245 | $9.97 | $251,692.65 |
DisclosureSEC source: 0001209191-20-036624 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,098 Read SEC document |
| June 09, 2020 Filed Jun 12, 2020 00:09 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 25,748 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036128 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,343 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 26,911 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-20-008732 · doc4.xml · derivative · entry 6 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,063 Underlying: Common stock · 26,911 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. F3 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/29/2016. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 1,185 | $0.00 Strike: $6.15 | $0.00 |
DisclosureSEC source: 0001209191-20-008732 · doc4.xml · derivative · entry 5 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,815 Underlying: Common stock · 1,185 shares Expires 2027-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/23/2017. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon stock | 26,911 | $4.80 | $129,172.80 |
DisclosureSEC source: 0001209191-20-008732 · doc4.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,137 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. Read SEC document |
| February 11, 2020 Filed Feb 12, 2020 21:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon stock | 1,185 | $6.15 | $7,287.75 |
DisclosureSEC source: 0001209191-20-008732 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,226 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 393,950 | $0.00 Strike: $11.86 | $0.00 |
DisclosureSEC source: 0001209191-20-005973 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 393,950 Underlying: Common Stock · 393,950 shares Expires 2030-01-29 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| June 10, 2019 Filed Jun 13, 2019 00:52 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 19,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036578 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,595 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| January 22, 2019 Filed Jan 24, 2019 21:06 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 220,000 | $0.00 Strike: $15.47 | $0.00 |
DisclosureSEC source: 0001209191-19-005129 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2029-01-21 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2019 Filed Jul 18, 2019 16:06 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $2.34 | $0.00 |
DisclosureSEC source: 0001567619-19-014977 · doc1.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2029-01-02 F1 · derivative.exercise_date: The shares underlying the option shall vest on the first anniversary of the date of grant. Read SEC document |
| November 16, 2018 Filed Jan 22, 2019 21:16 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 32,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004733 · doc5.xml · nonDerivative · entry 2 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by Red Fish Blue Fish Revocable Trust Disclosed balance after: 1,768,976 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the purchase or sale of securities. Read SEC document |
| November 16, 2018 Filed Jan 22, 2019 21:16 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GiftCommon Stock | 32,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-004733 · doc5.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,041 F1 · kind: This is a bona fide gift transaction exempt under Section 16(b). This transaction did not involve the purchase or sale of securities. Read SEC document |
| November 06, 2018 Filed Nov 9, 2018 21:03 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 26,041 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-18-057931 · doc4.xml · derivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,974 Underlying: Common stock · 26,041 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/29/2016. Read SEC document |
| November 06, 2018 Filed Nov 9, 2018 21:03 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 26,041 | $4.80 | $124,996.80 |
DisclosureSEC source: 0001209191-18-057931 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,026 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents options exercised Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 23:24 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantCOMMON STOCK | 5,822 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-037894 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,172 F1 · shares: Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| May 31, 2018 Filed Jun 1, 2018 19:12 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $4.24 | $0.00 |
DisclosureSEC source: 0001587221-18-000029 · edgar.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-16 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 16, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on May 31, 2018. F2 · derivative.exercise_date: The shares underlying the stock option vest in equal monthly installments over a four-year period, beginning on May 16, 2018, so that all shares shall have vested on April 16, 2022. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 21:24 UTC | Kura Oncology, Inc. KURA · Entity 4871 | GrantOption to purchase common stock · Derivative | 275,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005590 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,000 Underlying: Common Stock · 275,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on the grant date. Read SEC document |
| January 02, 2018 Filed Mar 2, 2018 19:13 UTC | Zosano Pharma Corp ZSAN · Entity 12518 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001587221-18-000006 · edgar.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-01-02 F1 · derivative.exercise_price: As a result of a 1-for-20 reverse stock split of the common stock of the Company, which became effective at 5:00 p.m. Eastern Time on January 25, 2018 (the "Reverse Split"), the exercise price has increased from $0.53 per share to $10.60 per share. F2 · shares: As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares. F3 · derivative.exercise_date: The shares underlying the option shall vest on the first anniversary of the date of grant. F2 · derivative.underlying_shares: As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares. F2 · balance_after: As a result of the Reverse Split, the number of shares of the Company's common stock underlying the stock option has decreased from 30,000 shares to 1,500 shares. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 27,985 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-17-049932 · doc4.xml · derivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,015 Underlying: Common stock · 27,985 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an option exercise. F2 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/29/2016. Read SEC document |
| August 22, 2017 Filed Aug 23, 2017 20:13 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionCommon Stock | 27,985 | $4.80 | $134,328.00 |
DisclosureSEC source: 0001209191-17-049932 · doc4.xml · nonDerivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,985 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents an option exercise. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 22:11 UTC | PUMA BIOTECHNOLOGY, INC. PBYI · Entity 5478 | GrantStock Option (Right to Buy) · Derivative | 7,604 | $0.00 Strike: $79.20 | $0.00 |
DisclosureSEC source: 0001209191-17-039914 · doc4.xml · derivative · entry 1 WILSON TROY EDWARD · CIK 0001589597 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,604 Underlying: Common Stock · 7,604 shares Expires 2027-06-11 F1 · derivative.exercise_date: The option vests in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| April 21, 2017 Filed Apr 24, 2017 21:04 UTC | Kura Oncology, Inc. KURA · Entity 4871 | Exercise / conversionOption to purchase common stock · Derivative | 5,000 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001209191-17-027996 · doc4.xml · derivative · entry 4 WILSON TROY EDWARD · CIK 0001589597 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common stock · 5,000 shares Expires 2026-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vests in 48 equal monthly installments commencing on 1/29/16. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.